INDICATION
ENHERTU is a HER2-directed antibody and topoisomerase inhibitor
conjugate
indicated:
-
HER2-Positive Locally Advanced or
Metastatic
Gastric Cancer
-
As monotherapy for the treatment of adult patients with
locally
advanced or metastatic HER2-positive (IHC 3+ or IHC
2+/ISH positive)
gastric or gastroesophageal junction (GEJ)
adenocarcinoma who have
received a prior trastuzumab-based regimen
Contraindications
None.
Warnings and
Precautions
Interstitial
Lung Disease / Pneumonitis
Severe, life-threatening, or fatal interstitial lung disease (ILD),
including pneumonitis, can occur in patients treated with ENHERTU. A
higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in
patients with moderate renal impairment. Advise patients to immediately
report cough, dyspnea, fever, and/or any new or worsening respiratory
symptoms. Monitor patients for signs and symptoms of ILD. Promptly
investigate evidence of ILD. Evaluate patients with suspected ILD by
radiographic imaging. Consider consultation with a pulmonologist. For
asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved
to Grade 0, then if resolved in ≤28 days from date of onset, maintain
dose. If resolved in >28 days from date of onset, reduce dose 1
level. Consider corticosteroid treatment as soon as ILD/pneumonitis is
suspected (e.g., ≥0.5 mg/kg/day prednisolone or equivalent). For
symptomatic ILD/pneumonitis (Grade 2 or greater), permanently
discontinue ENHERTU. Promptly initiate systemic corticosteroid treatment
as soon as ILD/pneumonitis is suspected (e.g., ≥1 mg/kg/day prednisolone
or equivalent) and continue for at least 14 days followed by gradual
taper for at least 4 weeks.
HER2-Positive Locally Advanced or Metastatic Gastric
Cancer (6.4 mg/kg)
In patients with locally advanced or metastatic HER2-positive gastric or
GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, ILD occurred in 10%
of patients. Median time to first onset was 2.8 months (range: 1.2 to
21).
Neutropenia
Severe neutropenia, including febrile neutropenia, can
occur in patients treated with ENHERTU. Monitor complete blood counts
prior to initiation of ENHERTU and prior to each dose, and as clinically
indicated. For Grade 3 neutropenia (Absolute Neutrophil Count [ANC]
<1.0 to 0.5 x 109/L), interrupt ENHERTU until resolved to
Grade 2 or less, then maintain dose. For Grade 4 neutropenia (ANC <0.5 x 109/L), interrupt
ENHERTU until resolved to Grade 2 or less, then reduce dose by 1
level. For febrile neutropenia (ANC <1.0 x 109/L and
temperature >38.3º C or a sustained temperature of ≥38º C for more
than 1 hour), interrupt ENHERTU until resolved, then reduce dose by 1
level.
HER2-Positive Locally Advanced or Metastatic Gastric
Cancer (6.4 mg/kg)
In patients with locally advanced or metastatic HER2-positive gastric or
GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, a decrease in
neutrophil count was reported in 72% of patients. Fifty-one percent had
Grade 3 or 4 decreased neutrophil count. Median time to first onset of
decreased neutrophil count was 16 days (range: 4 to 187). Febrile
neutropenia was reported in 4.8% of patients.
Left Ventricular
Dysfunction
Patients treated with ENHERTU may be at increased risk of developing
left ventricular dysfunction. Left ventricular ejection fraction (LVEF)
decrease has been observed with anti-HER2 therapies, including ENHERTU.
Assess LVEF prior to initiation of ENHERTU and at regular intervals
during treatment as clinically indicated. Manage LVEF decrease through
treatment interruption. When LVEF is >45% and absolute decrease from
baseline is 10-20%, continue treatment with ENHERTU. When LVEF is 40-45%
and absolute decrease from baseline is <10%, continue
treatment with
ENHERTU and repeat LVEF assessment within 3 weeks. When LVEF is
40-45% and absolute decrease from baseline is 10-20%, interrupt
ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF has not
recovered to within 10% from baseline, permanently discontinue
ENHERTU. If LVEF recovers to within 10% from baseline, resume
treatment with ENHERTU at the same dose. When LVEF is
<40% or
absolute decrease from baseline is >20%, interrupt ENHERTU and repeat
LVEF assessment within 3 weeks. If LVEF of <40% or
absolute decrease
from baseline of >20% is confirmed, permanently discontinue
ENHERTU. Permanently discontinue ENHERTU in patients with
symptomatic congestive heart failure. Treatment with ENHERTU has
not been studied in patients with a history of clinically
significant cardiac disease or LVEF <50% prior to
initiation of
treatment.
HER2-Positive Locally Advanced or Metastatic Gastric Cancer (6.4
mg/kg)
In patients with locally advanced or metastatic HER2-positive gastric or
GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, no clinical adverse
events of heart failure were reported; however, on echocardiography, 8%
were found to have asymptomatic Grade 2 decrease in LVEF.
Embryo-Fetal
Toxicity
ENHERTU can cause fetal harm when administered to a
pregnant woman.
Advise patients of the potential risks to a fetus.
Verify the pregnancy
status of females of reproductive potential prior to the
initiation of
ENHERTU. Advise females of reproductive potential to use
effective
contraception during treatment and for 7 months after
the last dose of
ENHERTU. Advise male patients with female partners of
reproductive
potential to use effective contraception during
treatment with ENHERTU
and for 4 months after the last dose of ENHERTU.
Additional Dose
Modifications
Thrombocytopenia
For Grade 3 thrombocytopenia (platelets
<50 to 25 x
109/L) interrupt ENHERTU until resolved to
Grade 1 or less,
then maintain dose. For Grade 4 thrombocytopenia
(platelets <25 x
109/L) interrupt ENHERTU until resolved to
Grade 1 or less,
then reduce dose by 1 level.
Adverse
Reactions
The safety of ENHERTU was evaluated in 187 patients with locally
advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma in
DESTINY-Gastric01. Patients intravenously received at least 1 dose of
either ENHERTU (N=125) 6.4 mg/kg every 3 weeks or either irinotecan
(N=55) 150 mg/m2 biweekly or paclitaxel (N=7) 80
mg/m2 weekly for 3 weeks. The median duration of treatment
was 4.6 months (range: 0.7 to 22.3) for patients who received ENHERTU.
Serious adverse reactions occurred in 44% of patients receiving ENHERTU
6.4 mg/kg. Serious adverse reactions in >2% of patients who received
ENHERTU were decreased appetite, ILD, anemia, dehydration, pneumonia,
cholestatic jaundice, pyrexia, and tumor hemorrhage. Fatalities due to
adverse reactions occurred in 2.4% of patients: disseminated
intravascular coagulation, large intestine perforation, and pneumonia
occurred in 1 patient each (0.8%).
ENHERTU was permanently discontinued in 15% of patients, of which ILD
accounted for 6%. Dose interruptions due to adverse reactions occurred
in 62% of patients treated with ENHERTU. The most frequent adverse
reactions (>2%) associated with dose interruption were neutropenia,
anemia, decreased appetite, leukopenia, fatigue, thrombocytopenia, ILD,
pneumonia, lymphopenia, upper respiratory tract infection, diarrhea, and
decreased blood potassium. Dose reductions occurred in 32% of patients
treated with ENHERTU. The most frequent adverse reactions (>2%)
associated with dose reduction were neutropenia, decreased appetite,
fatigue, nausea, and febrile neutropenia.
The most common (≥20%) adverse reactions, including laboratory
abnormalities, were decreased hemoglobin (75%), decreased white blood
cell count (74%), decreased neutrophil count (72%), decreased lymphocyte
count (70%), decreased platelet count (68%), nausea (63%), decreased
appetite (60%), increased aspartate aminotransferase (58%), fatigue
(55%), increased blood alkaline phosphatase (54%), increased alanine
aminotransferase (47%), diarrhea (32%), decreased blood potassium (30%),
vomiting (26%), constipation (24%), increased blood bilirubin (24%),
pyrexia (24%), and alopecia (22%).
Use in Specific
Populations
-
Pregnancy:
ENHERTU can cause
fetal harm when administered to a pregnant woman.
Advise patients of
the potential risks to a fetus. There are clinical
considerations if
ENHERTU is used in pregnant women, or if a patient
becomes pregnant
within 7 months after the last dose of ENHERTU.
-
Lactation:
There are no data
regarding the presence of ENHERTU in human milk, the
effects on the
breastfed child, or the effects on milk production.
Because of the
potential for serious adverse reactions in a
breastfed child, advise
women not to breastfeed during treatment with
ENHERTU and for 7
months after the last dose.
-
Females and Males of
Reproductive
Potential:
Pregnancy testing: Verify pregnancy status of
females of
reproductive potential prior to initiation of
ENHERTU. Contraception:
Females: ENHERTU can cause fetal harm when
administered to
a pregnant woman. Advise females of reproductive
potential to use
effective contraception during treatment with
ENHERTU and for 7
months after the last dose. Males: Advise
male patients
with female partners of reproductive potential to
use effective
contraception during treatment with ENHERTU and for
4 months after
the last dose. Infertility: ENHERTU may impair male reproductive function and fertility.
-
Pediatric
Use:
Safety and
effectiveness of ENHERTU have not been established
in pediatric
patients.
-
Geriatric
Use:
Of the 125 patients with HER2-positive locally advanced or
metastatic gastric or GEJ adenocarcinoma treated with ENHERTU 6.4
mg/kg in DESTINY-Gastric01, 56% were ≥65 years and 14% were ≥75
years. No overall differences in efficacy or safety were observed
between patients ≥65 years of age compared to younger patients.
-
Renal
Impairment:
A higher
incidence of Grade 1 and 2 ILD/pneumonitis has been
observed in
patients with moderate renal impairment. Monitor
patients with
moderate renal impairment more frequently. The
recommended dosage of
ENHERTU has not been established for patients with
severe renal
impairment (CLcr <30 mL/min).
-
Hepatic
Impairment:
In
patients with moderate hepatic impairment, due to
potentially
increased exposure, closely monitor for increased
toxicities related
to the topoisomerase inhibitor, DXd. The recommended
dosage of ENHERTU
has not been established for patients with severe
hepatic impairment
(total bilirubin >3 times ULN and any AST).
To report SUSPECTED
ADVERSE
REACTIONS, contact Daiichi Sankyo, Inc. at
1-877-437-7763 or FDA at
1-800-FDA-1088 or fda.gov/medwatch.
Please click here for full Prescribing Information, including Boxed WARNINGS, and click here for Medication Guide.
